As US FDA approves promising new HIV drug dolutegravir, MSF asks when people in developing countries will have access
8-16 | As the US Food and Drug Administration approved the new HIV drug dolutegravir on 13 Aug, Médecins Sans Frontières (MSF) questioned when people in developing countries would be able to access this promising new drug. Studies have shown dolutegravir, a drug from the potent new integrase inhibitor class of drugs, to be well-tolerated and extremely effective in stopping replication of the HIV virus, with a high barrier to HIV resistance.
7-2 | MSF pricing analysis also extends to HIV diagnostic and monitoring tools
5-13 | Iraq MSF issued a report Healing Iraqis: The Challenges of Providing Mental Health Care in Iraq, recording examples of the impact constant day to day violence have had on the Iraqis. It said there is an urgent need to scale up mental health care services in the country, and called on the Ministry of Health to improve the quality and access to mental health services. Yemen
4-9 | Everyday, 600 children and 4,000 adults die of a treatable and manageable disease. After decades of struggle against HIV/AIDS there is still an urgent need to do more to stop people dying needlessly. Despite available and mostly affordable drugs, tools and models of care that work, is it acceptable that 1.7 million people succumb to the disease every year? I don’t think so.
Sluggish response risks squandering historic opportunity to tackle global drug-resistant tuberculosis
3-20 | People living with MDR-TB and their healthcare providers call for urgent action